Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

By S. Yusuf, P. Sleight, Janice Pogue, J. Bosch, R. Davies, G. Dagenais. 2000

3,011 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Metformin: An Update (2002, background): “Diabetic patients have a higher incidence of hypertension compared with the general population, and hypertensive persons are more prone to develop diabetes (90, 91).”
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017, background): “Treatment with ACE inhibitors is recommended in patients with systolic LV dysfunction or heart failure, hypertension, or diabetes, and should be considered in all STEMI patients.(394,395) Patients who do not tolerate an ACE inhibitor should be given an angiotensin II receptor blocker (ARB).”
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. (2007, background): “ers (ARBs) in reducing morbidity and mortality in diabetes, hypertension, atherosclerosis, heart failure, and stroke (69, 77, 168, 220).”